Literature DB >> 17876378

Fasting but not postprandial (postmeal) glycemia predicts the risk of death in subjects with coronary artery disease.

Anil Nigam1, Martial G Bourassa, Annik Fortier, Marie-Claude Guertin, Jean-Claude Tardif.   

Abstract

BACKGROUND: Chronic hyperglycemia plays a role in the pathogenesis of coronary artery disease (CAD); however, the cut-off level beyond which glycemia becomes detrimental is still controversial. Postprandial glycemia may be a stronger CAD risk factor than fasting glycemia in patients without documented heart disease.
OBJECTIVES: To identify the contributions of fasting and postprandial glycemia to cardiovascular risk in patients with documented coronary artery disease.
METHODS: The Coronary Artery Surgery Study (CASS) registry is a database of 24,958 patients with suspected or proven CAD who underwent cardiac catheterization between 1974 and 1979. Median long-term follow up was 14.7 years (interquartile range 9.8 to 16.2 years). Clinical outcomes were evaluated according to fasting glucose levels and 2 h postprandial (postmeal) plasma glucose (2hPG) levels. A total of 13,176 patients with baseline fasting glucose levels and 1691 patients with 2hPG levels were identified.
RESULTS: Impaired fasting glycemia was associated with a 1.2-fold increase in both all-cause and cardiovascular mortality (adjusted hazard ratio 1.23; 95% CI 1.08 to 1.40 for cardiovascular mortality), while undiagnosed diabetes was associated with a 1.5-fold increased risk for the same end points. Postprandial hyperglycemia (2hPG of 7.8 mmol/L to 11.0 mmol/L following an average meal) was not associated with a significant risk of death after adjustment for traditional risk factors or in the presence of fasting glucose of less than 6.1 mmol/L.
CONCLUSIONS: In CAD patients, impaired fasting glucose is associated with increased all-cause and cardiovascular mortality, whereas postprandial hyperglycemia following an average meal does not appear to be a risk factor.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17876378      PMCID: PMC2651364          DOI: 10.1016/s0828-282x(07)70842-5

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  32 in total

1.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.

Authors:  I M Stratton; A I Adler; H A Neil; D R Matthews; S E Manley; C A Cull; D Hadden; R C Turner; R R Holman
Journal:  BMJ       Date:  2000-08-12

2.  Impaired fasting glucose concentrations in nondiabetic patients with ischemic heart disease: a marker for a worse prognosis.

Authors:  E Z Fisman; M Motro; A Tenenbaum; V Boyko; L Mandelzweig; S Behar
Journal:  Am Heart J       Date:  2001-03       Impact factor: 4.749

3.  The significance of impaired fasting glucose versus impaired glucose tolerance: importance of insulin secretion and resistance.

Authors:  Gian Piero Carnevale Schianca; Antonello Rossi; Pier Paolo Sainaghi; Elisabetta Maduli; Ettore Bartoli
Journal:  Diabetes Care       Date:  2003-05       Impact factor: 19.112

4.  Association between postprandial hyperinsulinemia and coronary artery disease among non-diabetic women: a case control study.

Authors:  Mehmet Baltali; Mehmet E Korkmaz; H Tarik Kiziltan; I Haldun Muderris; Bulent Ozin; Ruksan Anarat
Journal:  Int J Cardiol       Date:  2003-04       Impact factor: 4.164

5.  Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria.

Authors: 
Journal:  Arch Intern Med       Date:  2001-02-12

6.  Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases?

Authors: 
Journal:  Diabetes Care       Date:  2003-03       Impact factor: 19.112

7.  Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention.

Authors:  Joseph B Muhlestein; Jeffrey L Anderson; Benjamin D Horne; Farangis Lavasani; Chloe A Allen Maycock; Tami L Bair; Robert R Pearson; John F Carlquist
Journal:  Am Heart J       Date:  2003-08       Impact factor: 4.749

8.  Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.

Authors:  Jean-Louis Chiasson; Robert G Josse; Ramon Gomis; Markolf Hanefeld; Avraham Karasik; Markku Laakso
Journal:  JAMA       Date:  2003-07-23       Impact factor: 56.272

9.  Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study.

Authors:  James B Meigs; David M Nathan; Ralph B D'Agostino; Peter W F Wilson
Journal:  Diabetes Care       Date:  2002-10       Impact factor: 19.112

10.  Differences in insulin resistance in nondiabetic subjects with isolated impaired glucose tolerance or isolated impaired fasting glucose.

Authors:  Andreas Festa; Ralph D'Agostino; Anthony J G Hanley; Andrew J Karter; Mohammed F Saad; Steven M Haffner
Journal:  Diabetes       Date:  2004-06       Impact factor: 9.461

View more
  2 in total

Review 1.  Impact of postprandial glycaemia on health and prevention of disease.

Authors:  E E Blaak; J-M Antoine; D Benton; I Björck; L Bozzetto; F Brouns; M Diamant; L Dye; T Hulshof; J J Holst; D J Lamport; M Laville; C L Lawton; A Meheust; A Nilson; S Normand; A A Rivellese; S Theis; S S Torekov; S Vinoy
Journal:  Obes Rev       Date:  2012-07-11       Impact factor: 9.213

2.  Impaired fasting glucose and risk of cardiovascular disease in Korean men and women: the Korean Heart Study.

Authors:  Hong-Kyu Kim; Chul-Hee Kim; Eun Hee Kim; Sung Jin Bae; Jaewon Choe; Joong-Yeol Park; Seong-Wook Park; Young Duk Yun; Soo-Jin Baek; Yejin Mok; Sun Ha Jee
Journal:  Diabetes Care       Date:  2012-09-21       Impact factor: 19.112

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.